title: [Auer rods-positive neutrophils observed at diagnosis increased after remission induction in patient with acute promyelocytic leukemia].
abstract: 50-year-old male was admitted to our hospital because of gingival bleeding and fever in August 1987. The leukocyte count was 13,300/microliters with 80.5% leukemic promyelocytes and bone marrow was hypercellular with 86.4% leukemic promyelocytes. A small number of mature neutrophils containing Auer rods were seen in bone marrow. On a diagnosis of acute promyelocytic leukemia and treated with induction chemotherapy consisting of behenoyl-arabinofuranosyl cytosine (BHAC), daunorubicin, 6-mercaptopurine (6-MP) and prednisolone (PSL) was reformed. After cytoreduction, leukemic cells reappeared in the peripheral blood, concomitant with mature neutrophils having Auer rods. Vitamin D3 was not effective as a differentiation inducing agent. Complete remission was obtained in November 1987 by the reinduction chemotherapy consisting of BHAC, aclarubicin, 6-MP and PSL. In this case, neutrophils with Auer rods might have been derived from the leukemic clone and differentiation of leukemic promyelocytes by intensive chemotherapy.
authors.affiliation: Second Department of Medicine, Kyoto Prefectural University of Medicine.
authors.forename: E
authors.initials: E
authors.lastname: Ashihara
authors.forename: K
authors.initials: K
authors.lastname: Ohkawa
authors.forename: H
authors.initials: H
authors.lastname: Gotoh
authors.forename: N
authors.initials: N
authors.lastname: Oku
authors.forename: T
authors.initials: T
authors.lastname: Inaba
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: K
authors.initials: K
authors.lastname: Itoh
authors.forename: N
authors.initials: N
authors.lastname: Fujita
authors.forename: C
authors.initials: C
authors.lastname: Shimazaki
authors.forename: A
authors.initials: A
authors.lastname: Nishio
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D002479:Inclusion Bodies / Q000187:drug effects / Q000473:pathology*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology*; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D011239:Prednisolone; C015019:enocitabine; D015122:Mercaptopurine; D003630:Daunorubicin